Clinical trial · Interventional
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
Effect of Liraglutide on Different Parameters (Clinical , Metabolic and Hormonal) in Obese Women With Polycystic Ovary Syndrome
NCT05965908CI-TRIAL-00123656completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the hormonal, metabolic and clinical effects of metformin and liraglutide in infertile women with PCOs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| liraglutide | Drug | — | UNRESOLVED |
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- liraglutide
- description
- will receive the drug via daily subcutaneous injection to ensure optimal tolerability, the dose was titrated upward weekly by increments of 0.6 mg (i.e., 1.2 mg/day in week 2, 1.8 mg/day in week 3, 2.4 mg/day in week 4) until reaching the target therapeutic dose of 3.0 mg/day for 6-month study duration.
- interventionNames
- Drug: liraglutide
- type
- ACTIVE_COMPARATOR
- label
- metformin
- description
- the patient is given Glucophage 1000 mg tab once daily after lunch for 6 months
- interventionNames
- Drug: Metformin
- type
- NO_INTERVENTION
- label
- control
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * women aged 18-45 years * Poly cystic ovary syndrome based on the Rotterdam criteria Exclusion Criteria: 1. congenital adrenal hyperplasia, 2. poorly controlled thyroid disease 3. Taking antidiabetic drugs which can affect insulin resistance 4. chronic kidney disease 5. liver dysfunction (AST or ALT 6. Documented use of oral hormonal contraceptives and hormone-releasing implants 7. intolerance or allergy to liraglutide or metformin
References
Publications (0)
Data not yet available
No reference posted for this study.